New antibiotic under watch for High-Risk patients

NCT ID NCT06864585

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study aims to monitor the safety and real-world effectiveness of the antibiotic Zavicefta in Japan. It will include about 59 patients who have severe bloodstream infections (sepsis) or reduced kidney function and are receiving Zavicefta for the first time. Researchers will track any side effects and how well the treatment works over 28 days.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.